Early Detection Research Network

PLCO Ovarian Phase III Validation Study

Our preliminary data indicate that the performance of CA 125 as a screening test for ovarian cancer can be improved upon by additional biomarkers. With completion of one additional validation step, we will be ready to test the performance of a consensus marker panel in a phase III validation study. Given the original aims of the PLCO trial, we believe that the PLCO represents an ideal longitudinal cohort offering specimens for phase III validation of ovarian cancer biomarkers.
312-plco-ovarian-phase-iii-validation-study
683d8e8b465a4105baa8594734b0fa61
683d8e8b465a4105baa8594734b0fa61
Contents

There are currently no items in this folder.